Literature DB >> 4082086

Questions and answers on prothrombin time standardisation in oral anticoagulant control.

E A Loeliger, L Poller, M Samama, J M Thomson, A M Van den Besselaar, J Vermylen, M Verstraete.   

Abstract

One of the reasons why oral anticoagulants fell into disrepute is the absence of internationally accepted standardised procedures for controlling the level of anticoagulation. This deplorable situation resulted in over- and under-coagulation and uncertainty in the therapeutic range. International conformity can now be obtained by using an International Normalised Ratio (INR) which is derived from the individual result obtained in a given plasma sample and the International Sensitivity Index (ISI) of the tissue thromboplastin reagent used. Any thromboplastin reagent can be calibrated against an international primary or secondary W. H. O. reference preparation, so as to obtain its International Sensitivity Index. The new system of reporting the level of anticoagulation was designed and can only safely be applied in patients taking oral anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4082086

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  10 in total

1.  Anticoagulation Management as a Risk Factor for Adverse Events: Grounds for Improvement.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998-01       Impact factor: 2.300

Review 2.  Therapeutic ranges for oral anticoagulation in different thromboembolic disorders.

Authors:  L Poller
Journal:  Ann Hematol       Date:  1992-02       Impact factor: 3.673

Review 3.  Clinical utilization of the international normalized ratio (INR).

Authors:  R S Riley; D Rowe; L M Fisher
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Control of oral anticoagulant treatment by chromogenic prothrombin assay.

Authors:  J R O'Donnell; I D Walker; J F Davidson
Journal:  J Clin Pathol       Date:  1987-05       Impact factor: 3.411

Review 5.  Drug treatment associated with heart valve replacement.

Authors:  D S Coulshed; M A Fitzpatrick; C H Lee
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

Review 6.  Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack.

Authors:  Peter A G Sandercock; Lorna M Gibson; Ming Liu
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

Review 7.  [Thrombosis prevention with heparin/dihydroergotamine versus heparin/Sintrom in Ender nailing of pertrochanteric fractures].

Authors:  G Schlag; T Gaudernak; H Pelinka; H Redl; H Kuderna; J Poigenfürst
Journal:  Unfallchirurgie       Date:  1988-02

8.  Increased tissue-plasminogen activator (t-PA) levels in patients under oral anticoagulant therapy.

Authors:  J Grulich-Henn; K Loechelt; W Speiser; G Müller-Berghaus
Journal:  Blut       Date:  1989-01

9.  Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric acute liver failure.

Authors:  David A Rudnick; Dennis J Dietzen; Yumirle P Turmelle; Ross Shepherd; Song Zhang; Steven H Belle; Rob Squires
Journal:  Pediatr Transplant       Date:  2008-07-17

10.  Continuous thrombin generation in whole blood: New applications for assessing activators and inhibitors of coagulation.

Authors:  Shannon M Prior; Kenneth G Mann; Kalev Freeman; Saulius Butenas
Journal:  Anal Biochem       Date:  2018-05-07       Impact factor: 3.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.